XTL Biopharmaceuticals Ltd ADR (XTLB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, XTL Biopharmaceuticals Ltd ADR (XTLB) has a cash flow conversion efficiency ratio of -0.502x as of December 2022. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.01 Million) by net assets ($4.00 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see XTL Biopharmaceuticals Ltd ADR market cap and net worth for the company's overall valuation and market capitalisation.
XTL Biopharmaceuticals Ltd ADR - Cash Flow Conversion Efficiency Trend (2003–2024)
This chart illustrates how XTL Biopharmaceuticals Ltd ADR's cash flow conversion efficiency has evolved over time, based on yearly financial data.
XTL Biopharmaceuticals Ltd ADR Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of XTL Biopharmaceuticals Ltd ADR ranked by their cash flow conversion efficiency. Explore earnings quality score of XTL Biopharmaceuticals Ltd ADR to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Youxin Technology Ltd Class A Ordinary shares
NASDAQ:YAAS
|
-0.202x |
|
SOLUTIANCE AG NA O.N.
F:SLSA
|
N/A |
|
Skye Bioscience, Inc. Common Stock
NASDAQ:SKYE
|
14.320x |
|
North Arrow Minerals Inc
V:NAR
|
-0.011x |
|
Nanotech Indonesia Global Tbk PT
JK:NANO
|
-0.010x |
|
BRADDA HEAD LITHIUM O.N.
F:8CD1
|
0.059x |
|
Winfarm
PA:ALWF
|
0.152x |
|
Euro Manganese Inc
V:EMN
|
3.655x |
Annual Cash Flow Conversion Efficiency for XTL Biopharmaceuticals Ltd ADR (2003–2024)
The table below shows the annual cash flow conversion efficiency of XTL Biopharmaceuticals Ltd ADR from 2003 to 2024. View current stock price of XTL Biopharmaceuticals Ltd ADR for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $5.43 Million | $-1.62 Million | -0.298x | +6.52% |
| 2023-12-31 | $2.22 Million | $-707.00K | -0.318x | -41.35% |
| 2022-12-31 | $4.00 Million | $-901.00K | -0.225x | -14.54% |
| 2021-12-31 | $5.33 Million | $-1.05 Million | -0.197x | -44.61% |
| 2020-12-31 | $6.25 Million | $-850.00K | -0.136x | -4.56% |
| 2019-12-31 | $6.98 Million | $-908.00K | -0.130x | -32.67% |
| 2018-12-31 | $8.32 Million | $-816.00K | -0.098x | +68.46% |
| 2017-12-31 | $3.62 Million | $-1.12 Million | -0.311x | +51.77% |
| 2016-12-31 | $2.69 Million | $-1.73 Million | -0.645x | -69.27% |
| 2015-12-31 | $4.89 Million | $-1.86 Million | -0.381x | +27.86% |
| 2014-12-31 | $4.68 Million | $-2.47 Million | -0.528x | -43.33% |
| 2013-12-31 | $6.79 Million | $-2.50 Million | -0.368x | -130.48% |
| 2012-12-31 | $9.42 Million | $-1.51 Million | -0.160x | +69.44% |
| 2011-12-31 | $3.44 Million | $-1.80 Million | -0.523x | -101.63% |
| 2010-12-31 | $2.83 Million | $-735.00K | -0.259x | +99.93% |
| 2009-12-31 | $7.00K | $-2.49 Million | -355.429x | -4691.46% |
| 2008-12-31 | $1.43 Million | $-10.58 Million | -7.418x | -196.07% |
| 2007-12-31 | $8.56 Million | $-21.46 Million | -2.505x | -353.05% |
| 2006-12-31 | $22.76 Million | $-12.59 Million | -0.553x | +40.54% |
| 2005-12-31 | $11.25 Million | $-10.47 Million | -0.930x | -25.79% |
| 2004-12-31 | $19.60 Million | $-14.49 Million | -0.739x | -14.35% |
| 2003-12-31 | $20.61 Million | $-13.33 Million | -0.647x | -- |
About XTL Biopharmaceuticals Ltd ADR
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. The company has a licensing agreement with Yeda Research and Development Company L… Read more